Pharmacological strategies for overcoming multidrug resistance.
about
Cancer stem cells and drug resistance: the potential of nanomedicineWhere is it and How Does it Get There - Intracellular Localization and Traffic of P-glycoproteinSmall and Innovative Molecules as New Strategy to Revert MDRTamoxifen regulation of sphingolipid metabolism--Therapeutic implicationsBeyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancersDelivery of molecules into cells using carbon nanoparticles activated by femtosecond laser pulses.Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells.Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavirRecent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesClinical significance of ABCB1 genotyping in oncology.Uptake of compounds that selectively kill multidrug-resistant cells: the copper transporter SLC31A1 (CTR1) increases cellular accumulation of the thiosemicarbazone NSC73306Reversal of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR by LY980503.Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapyMarine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cellsSynthetic Utility of Epoxides for Chiral Functionalization of Isoxazoles.Effects of Astragalus polysaccharides on P-glycoprotein efflux pump function and protein expression in H22 hepatoma cells in vitroNanodiamond-mitoxantrone complexes enhance drug retention in chemoresistant breast cancer cellsRecent advances in candidate-gene and whole-genome approaches to the discovery of anthelmintic resistance markers and the description of drug/receptor interactions.A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.Glucocorticosteroids: current and future directions.P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells.Reversal of multidrug resistance by 5,5'-dimethoxylariciresinol-4-O-β-D-glucoside in doxorubicin-resistant human leukemia K562/DOX.The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents.Cancer cell invasion: treatment and monitoring opportunities in nanomedicine.2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination.β-arrestin 2 is associated with multidrug resistance in breast cancer cells through regulating MDR1 gene expressionAPR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cellsLoperamide, an FDA-approved antidiarrhea drug, effectively reverses the resistance of multidrug resistant MCF-7/MDR1 human breast cancer cells to doxorubicin-induced cytotoxicity.A Novel Submicron Emulsion System Loaded with Doxorubicin Overcome Multi-Drug Resistance in MCF-7/ADR Cells4-Isoxazolyl-1,4-dihydropyridines exhibit binding at the multidrug-resistance transporterAstragalus polysaccharides can regulate cytokine and P-glycoprotein expression in H22 tumor-bearing mice.Paclitaxel nanocrystals for overcoming multidrug resistance in cancerOvercoming doxorubicin resistance of cancer cells by Cas9-mediated gene disruption.Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor.Vitamin E reverses multidrug resistance in vitro and in vivo.Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety.Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunitiesDevelopment of inhibitors of ATP-binding cassette drug transporters: present status and challenges.Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.
P2860
Q26998993-971A9FE4-2338-4F5D-8657-AAF05A31E1C2Q27008624-F122108E-EACB-4612-879C-E802370E3452Q27012455-4CE4531A-A68C-4D04-8656-8DAD5B25F3F0Q28084270-ED0D3F22-7EB1-45C3-8916-119DF9D1CCC5Q28743513-BFD3FEBC-DE35-44B4-91DB-E6FDE4D064F0Q30477374-5BF7E030-7732-4CF1-BCD8-26D08F0397B2Q33610153-EE26F5E2-4F7E-4743-8A8B-4B07605B7950Q33611816-33898BD9-65DC-487A-ACD0-3C149776D277Q33730375-CB9FE398-FE0A-4558-8697-3E82871A6FC7Q33951034-242EBC0C-1E06-4098-8A98-466CB3B5EE17Q34065942-17016FB6-0064-499F-8567-C68BF2F42060Q34098942-698449CA-E80B-479A-BC52-8F3B777B59ADQ34113542-BD893019-8C61-496B-A66F-5A92E87E21DFQ34166391-DC8AED80-22D9-45A3-B295-0BF690CB8AE5Q34333209-9F0DB02A-508D-49D0-BF79-C24DCDCCD537Q34333351-1F9046CF-F815-466C-9B29-BD7473D24E28Q34435737-4AC5E3DC-8759-4216-99EE-BFD32271C953Q34705912-6CDBB33A-1260-4E12-980B-539B5ECFDAD1Q34768677-B901F5B1-F567-4D59-AC10-D5789AF4ABCAQ34903070-2725D38D-9135-40B6-9B3E-91ED878CCB59Q35057879-4A704EBF-5F3C-4AA2-90FF-B92C7461E59CQ35069074-2C69D0A2-97B2-4462-9ED3-F50E91387657Q35076888-2213CE8E-0944-481D-BF99-F00797D19A85Q35093966-226F9E16-3346-40D0-90D6-545FDE273FECQ35110635-5C8225C2-BB65-4489-855C-311F7BE4414DQ35130652-ECE50447-7B28-4D13-8108-710D30D35A4DQ35406094-26381095-609F-4F27-A4DA-BC644EFE98B2Q35667409-E079F2FF-3E6F-4E88-895A-AF7A15BC54EDQ35834576-2890230F-B66B-4EEE-8399-23555D35E010Q36291842-A582BCBB-5C4A-4E03-A005-1463917ABAC2Q36341893-71BE7E58-F1AD-4FD0-9A33-BA8A91E560FDQ36492677-835A9D99-61A1-41B2-B09B-8226D904CE7BQ36623275-55DB2A75-1385-47BA-A496-5573198C92F5Q36670889-77E8192F-1241-4405-8425-D84B777EDD82Q36788463-10B01945-A226-4F2A-A3F8-982815C41A60Q36936239-831C1FA0-3ED6-4745-A7FD-887142BE3E61Q36960535-117833CF-0E99-48FA-99D5-518DC5AB9158Q36960756-D31299AE-0DF7-46B3-B061-0791502A591EQ37076348-9C131ACC-F289-4DDC-874C-223C595074B4Q37144023-B0B32282-F6E2-4D4A-9D59-D0CF94E416FF
P2860
Pharmacological strategies for overcoming multidrug resistance.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Pharmacological strategies for overcoming multidrug resistance.
@ast
Pharmacological strategies for overcoming multidrug resistance.
@en
type
label
Pharmacological strategies for overcoming multidrug resistance.
@ast
Pharmacological strategies for overcoming multidrug resistance.
@en
prefLabel
Pharmacological strategies for overcoming multidrug resistance.
@ast
Pharmacological strategies for overcoming multidrug resistance.
@en
P2093
P1433
P1476
Pharmacological strategies for overcoming multidrug resistance.
@en
P2093
P304
P356
10.2174/138945006777709593
P577
2006-07-01T00:00:00Z